Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).
Amit Bahl
Consultant or Advisory Role - Sanofi ; Sanofi
Honoraria - Sanofi ; Sanofi
Research Funding - Sanofi ; Sanofi
Susan Masson
Research Funding - Sanofi
Zafar I. Malik
Honoraria - Sanofi
Alison J. Birtle
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Honoraria - Janssen Pharmaceutical ; Sanofi
Santhanam Sundar
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Robert J. Jones
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Nicholas David James
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Malcolm David Mason
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
David Bottomley
No relevant relationships to disclose
Anna Lydon
Consultant or Advisory Role - Sanofi
Simon Chowdhury
Consultant or Advisory Role - Sanofi
James Wylie
No relevant relationships to disclose
Johann Sebastian De Bono
Honoraria - Sanofi